×
Time:2024-01-13
Recently, NHU has secured approval for domestic drug registration of its API Coenzyme Q10, positioning the company as the first enterprise to receive such approval since the issuance of the National Medical Products Administration (NMPA)'s Announcement on Matters Related to Further Improving the Review, Approval, and Supervision of Drugs in 2019. This significant milestone indicates that our Coenzyme Q10 is at the forefront of the industry and paves the way for a new API market, presenting fresh opportunities for our development.
About Coenzyme Q10
Coenzyme Q10, a fat-soluble antioxidant, plays a crucial role in fortifying the myocardium, preventing heart aging, preventing and combating cancer, maintaining cardiovascular health, and enhancing overall vitality. The significant market demand for Coenzyme Q10 exists both domestically and internationally. The production of API Coenzyme Q10 necessitates stringent quality control and safety inspections, leading to rigorous requirements for production processes and product quality. NHU stands out as the inaugural company to receive such approval and recognition, demonstrating the company’s capability to produce high-quality API Coenzyme Q10 since the drug approval reform by the NMPA in 2019.
In its role as a guardian of nutrition and health, NHU is committed to the journey of open innovation. Starting from addressing future and potential market needs, we collaborate with academia and industry to delve into the cutting edges of chemical and biological science and technology and foster innovation and advancement, leading to the successful development of products like the Vitamin Series, Moxifloxacin Hydrochloride, and Taurine. NHU aims to create value for the entire industry and society, establishing a "Safety Moat" for human health.
NHU’s project, “Development and Industrialization of Integrated Manufacturing Technologies for High-Quality Solid Methionine” was awarded the First Prize of the Science and Technology Progress Award in recognition of its significant technological breakthroughs and industrial value.
View details
On December 12, the forum “Resilience, Symbiosis, Leadership – Release of the Top 100 Chinese Multinational Private Enterprises and the Zhejiang Business Think Tank Dialogue on the 15th Five-Year Plan” was successfully held in Hangzhou. At the event, the Center For Chinese Multinationals (CCM) of Zhejiang University Business School (ZIBS) released the Top 100 Chinese Multinational Private Enterprises 2025 list. NHU was honored to be included, in recognition of its forward-looking global strategy, robust and continuously innovative R&D system, and growing international influence.
View details
On December 4th, the 25th Fine Chemical Industry (Ningdong) Conference opened in Ningxia, where multiple rankings—including the 2025 China Top 100 Fine Chemical Companies—were officially released.
View details